Trust Point Inc. Buys 427 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Trust Point Inc. lifted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 25.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,100 shares of the medical equipment provider’s stock after buying an additional 427 shares during the period. Trust Point Inc.’s holdings in Intuitive Surgical were worth $1,032,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ISRG. NBC Securities Inc. increased its stake in shares of Intuitive Surgical by 34.4% in the first quarter. NBC Securities Inc. now owns 121 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 31 shares during the period. Massmutual Trust Co. FSB ADV raised its stake in shares of Intuitive Surgical by 7.8% during the first quarter. Massmutual Trust Co. FSB ADV now owns 930 shares of the medical equipment provider’s stock valued at $371,000 after acquiring an additional 67 shares during the last quarter. Montecito Bank & Trust acquired a new position in shares of Intuitive Surgical during the first quarter worth $324,000. Signal Advisors Wealth LLC bought a new stake in shares of Intuitive Surgical in the first quarter worth $203,000. Finally, Fulton Bank N.A. increased its holdings in Intuitive Surgical by 13.5% in the first quarter. Fulton Bank N.A. now owns 2,528 shares of the medical equipment provider’s stock valued at $1,009,000 after purchasing an additional 301 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Performance

ISRG traded up $41.73 during midday trading on Friday, reaching $515.46. 1,616,629 shares of the company were exchanged, compared to its average volume of 1,466,489. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $517.61. The company’s fifty day moving average price is $482.69 and its 200 day moving average price is $436.91. The company has a market cap of $182.83 billion, a price-to-earnings ratio of 92.56, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the prior year, the firm posted $1.18 EPS. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ISRG. Citigroup upped their price target on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Truist Financial upped their target price on Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a report on Monday. JPMorgan Chase & Co. raised their price target on shares of Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Morgan Stanley upped their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Finally, Mizuho lifted their target price on shares of Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday. Six research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $496.95.

Insider Transactions at Intuitive Surgical

In related news, EVP Robert Desantis sold 1,413 shares of the stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $438.60, for a total transaction of $619,741.80. Following the completion of the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,414,931.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Intuitive Surgical news, EVP Robert Desantis sold 1,413 shares of the company’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $438.60, for a total value of $619,741.80. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,414,931.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares in the company, valued at $1,461,006.84. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock worth $25,528,753 in the last 90 days. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.